Back to discover
Disease

B-cell non-Hodgkin's lymphoma

Late-stage therapeutic development
Also known as B-cell NHL, B-cell lymphoma, B-cell non Hodgkin's lymphoma, B-cell non-Hodgkin's lymphoma+3 more

B-cell NHL, B-cell lymphoma, B-cell non Hodgkin's lymphoma, B-cell non-Hodgkin's lymphoma, lymphomas non-Hodgkin's B-cell, non-Hodgkin's B-cell lymphoma, non-Hodgkin's lymphoma B-cell.

20
Clinical trials
12
Associated genes
1
Related proteins
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q1 2027.
  • 5 industry developments reported.
Upcoming Milestones
Clinical Milestones9View all 9
Results posted 3
Results expected 4
Recently completed 1
Other updates 1
+1 more in the activity timeline below
Industry & Market5View
Activity timeline14

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Odronextamabapproved

Approval — Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or… (2024)

Epcoritamabapproved

Approval — Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or… (2023)

Glofitamabapproved

Approval — Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of… (2023)

Pirtobrutinibapproved

Approval — Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or… (2023)

Lisocabtagene maraleucelapproved

Approval — Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymph… (2022)

Loncastuximab tesirineapproved

Approval — Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or… (2022)

Plerixaforapproved

Approval — Adult patients Plerixafor Accord is indicated in combination with granulocyte-colony stim… (2022)

Tafasitamabapproved

Approval — Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for… (2021)

Clinical trials

14 sponsors · 0 new · 1 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
3
Late-stage
6
Completed
Recently completed

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Phase 1/2 · Completed · Kite, A Gilead Company

A Pilot Study of Subcutaneous Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Phase 2 · Completed · University of Washington

Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma

Phase 2 · Completed · M.D. Anderson Cancer Center

Phase 2 Pilot Study to Evaluate Efficacy and Safety of Anakinra to Prevent CD19-Targeted CAR-T Cell-Related Cytokine Release Syndrome (CRS) and Neurotoxicity in Patients With B Cell Lymphoma

Phase 2 · Completed · Fred Hutchinson Cancer Center

A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma

Phase 2 · Completed · University of Washington

A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

Phase 2 · Completed · AstraZeneca

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApproval — Odronextamab· Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy. source ↗
2023emaApproval — Pirtobrutinib· Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a BTK inhibitor. source ↗
2023emaApproval — Epcoritamab· Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.  source ↗
2023emaApproval — Glofitamab· Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy. source ↗
2022emaApproval — Loncastuximab tesirine· Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. source ↗
2022emaApproval — Plerixafor· Adult patients Plerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2). Paediatric patients (1 to less than 18 years) Plerixafor Accord is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.2). source ↗
2022emaApproval — Lisocabtagene maraleucel· Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.   Breyanzi is indicated for the treatment of adult patients with relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy.  Breyanzi is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.   Breyanzi is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.  source ↗
2021emaApproval — Tafasitamab· Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). source ↗
Safety updates
2025emaMarket withdrawal — Bortezomib· Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation. source ↗
2024emaMarket withdrawal — Pixantrone dimaleate· Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy. source ↗
2024emaMarket withdrawal — Ibritumomab tiuxetan· Zevalin is indicated in adults. [90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

CD79B0.44MYD880.38MEF2B0.18ITSN20.15CD370.09TBRG10.06FDCSP0.01VPREB30.01ELL30.01SHLD30.00FAM90A10.00ZNF1120.00

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

B-cell antigen receptor complex-associated protein beta chainvia CD79B0.44

Reference

Authoritative identity, definition & identifiers.

Synonyms

B-cell NHL, B-cell lymphoma, B-cell non Hodgkin's lymphoma, B-cell non-Hodgkin's lymphoma, lymphomas non-Hodgkin's B-cell, non-Hodgkin's B-cell lymphoma, non-Hodgkin's lymphoma B-cell

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.